MA56553A - Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk - Google Patents

Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk

Info

Publication number
MA56553A
MA56553A MA056553A MA56553A MA56553A MA 56553 A MA56553 A MA 56553A MA 056553 A MA056553 A MA 056553A MA 56553 A MA56553 A MA 56553A MA 56553 A MA56553 A MA 56553A
Authority
MA
Morocco
Prior art keywords
pyrrolopyrimidinone
btk
tetrahydropyranyl
amino
treating
Prior art date
Application number
MA056553A
Other languages
English (en)
Other versions
MA56553B1 (fr
Inventor
Sudharshan Eathiraj
Hiroaki Inagaki
Jean-Marc Lapierre
Takayuki Momose
Kiyoshi Nakayama
Nivedita Namdev
Yusuke Ota
Brian Schwartz
Tomoyuki Tsunemi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MA56553A publication Critical patent/MA56553A/fr
Publication of MA56553B1 publication Critical patent/MA56553B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA56553A 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk MA56553B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (fr) 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA56553A true MA56553A (fr) 2022-04-27
MA56553B1 MA56553B1 (fr) 2023-04-28

Family

ID=59090991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56553A MA56553B1 (fr) 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk

Country Status (28)

Country Link
EP (2) EP3394065B1 (fr)
JP (1) JP6634520B2 (fr)
KR (2) KR20230098690A (fr)
CN (2) CN113307811B (fr)
AU (3) AU2015417922B2 (fr)
CA (1) CA3008446C (fr)
CY (1) CY1124210T1 (fr)
DK (2) DK3394065T3 (fr)
ES (2) ES2868884T3 (fr)
FI (1) FI3882250T3 (fr)
HR (2) HRP20230379T1 (fr)
HU (2) HUE055221T2 (fr)
IL (2) IL259938B (fr)
LT (2) LT3394065T (fr)
MA (1) MA56553B1 (fr)
MD (1) MD3882250T2 (fr)
MX (1) MX2018007815A (fr)
MY (1) MY193177A (fr)
PH (1) PH12018501390A1 (fr)
PL (2) PL3882250T3 (fr)
PT (2) PT3882250T (fr)
RS (2) RS61887B1 (fr)
RU (1) RU2715421C2 (fr)
SA (1) SA518391836B1 (fr)
SG (1) SG11201805154YA (fr)
SI (2) SI3394065T1 (fr)
WO (1) WO2017111787A1 (fr)
ZA (1) ZA201804091B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020398B2 (en) * 2016-08-24 2021-06-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN117551103A (zh) * 2019-11-13 2024-02-13 浙江龙传生物医药科技有限公司 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ－ピロロピリミジノンおよびその使用の方法
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技（苏州）有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (fr) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 Composé de pyrrolopyrimidinone et son utilisation
CN117794934A (zh) * 2021-05-12 2024-03-29 浙江龙传生物医药科技有限公司 吡咯并嘧啶类化合物的晶型及其制备方法
WO2023110970A1 (fr) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Inhibiteurs macrocycliques de btk
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN105906631A (zh) * 2009-11-18 2016-08-31 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
TW201522337A (zh) * 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並－嘧啶化合物類
US8940893B2 (en) 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
AU2019201737A1 (en) 2019-04-04
IL259938A (en) 2018-07-31
PT3394065T (pt) 2021-05-06
SI3394065T1 (sl) 2021-08-31
MA56553B1 (fr) 2023-04-28
HRP20230379T1 (hr) 2023-06-23
CN108699062A (zh) 2018-10-23
EP3394065A1 (fr) 2018-10-31
LT3882250T (lt) 2023-05-25
CN113307811B (zh) 2023-11-14
AU2020203690B2 (en) 2021-08-05
MY193177A (en) 2022-09-26
JP2018538349A (ja) 2018-12-27
ES2942743T3 (es) 2023-06-06
ZA201804091B (en) 2019-03-27
AU2015417922B2 (en) 2018-12-20
WO2017111787A1 (fr) 2017-06-29
CA3008446C (fr) 2023-10-10
KR102547188B1 (ko) 2023-06-26
PT3882250T (pt) 2023-04-21
SA518391836B1 (ar) 2022-06-19
CN108699062B (zh) 2021-06-29
IL282572B (en) 2022-04-01
CY1124210T1 (el) 2022-05-27
SG11201805154YA (en) 2018-07-30
CA3008446A1 (fr) 2017-06-29
MD3882250T2 (ro) 2023-06-30
SI3882250T1 (sl) 2023-07-31
RU2715421C2 (ru) 2020-02-28
HRP20210844T1 (hr) 2021-07-09
KR20230098690A (ko) 2023-07-04
DK3394065T3 (da) 2021-05-31
EP3394065A4 (fr) 2019-07-10
EP3394065B1 (fr) 2021-04-07
PH12018501390A1 (en) 2019-02-27
RS61887B1 (sr) 2021-06-30
HUE061761T2 (hu) 2023-08-28
RU2018126793A (ru) 2020-01-23
LT3394065T (lt) 2021-06-25
DK3882250T3 (da) 2023-05-22
HUE055221T2 (hu) 2021-11-29
JP6634520B2 (ja) 2020-01-22
FI3882250T3 (fi) 2023-04-27
RU2018126793A3 (fr) 2020-01-23
CN113307811A (zh) 2021-08-27
ES2868884T3 (es) 2021-10-22
KR20180096753A (ko) 2018-08-29
AU2019201737B2 (en) 2020-03-05
RS64141B1 (sr) 2023-05-31
AU2020203690A1 (en) 2020-06-25
IL282572A (en) 2021-06-30
MX2018007815A (es) 2019-07-04
BR112018012828A2 (pt) 2018-12-04
PL3394065T3 (pl) 2021-08-02
EP3882250B1 (fr) 2023-02-15
IL259938B (en) 2021-05-31
PL3882250T3 (pl) 2023-09-11
EP3882250A1 (fr) 2021-09-22
AU2015417922A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA56553A (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA46079A (fr) Procédé pour apporter un bénéfice à la peau
FR3050672B1 (fr) Automate pour le traitement d'une surface
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA45429A (fr) Polythérapie pour le traitement du cancer
BR112018000933A2 (pt) métodos de tratamento de um distúrbio de desenvolvimento
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
FR3017626B1 (fr) Procede pour le traitement thermique d'un rail en acier hypereutectoide
MA41555A (fr) Polythérapie pour le traitement du cancer
MA39722A (fr) Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41123A (fr) Polythérapie pour le traitement du cancer
FR3051127B1 (fr) Procede de traitement de surface pour objets
FR3027176B1 (fr) Rejeu d'un batch de commandes securisees dans un canal securise
MA40759A (fr) Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
DK3318115T3 (da) Maskine til behandling af svinegylle
FR3042807B1 (fr) Autolestage pour banche de coffrage
MA42252A (fr) Procédé de réalisation de réactions limitées à un équilibre
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA43944A (fr) Procédé de purification de liquide
DK3253407T3 (da) Brug af hla-b27-homodimere til kræftbehandling
FR3039765B1 (fr) Procede cosmetique de traitement des matieres keratiniques
FR3034242B1 (fr) Procede d'evaluation progressive de capacite a executer une tache, et plateforme de mise en oeuvre
FR3019767B1 (fr) Procede de traitement perfectionne d'une surface d'un element de friction